<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506571</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-261</org_study_id>
    <nct_id>NCT00506571</nct_id>
  </id_info>
  <brief_title>Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer</brief_title>
  <acronym>TIROX2</acronym>
  <official_title>Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on
      day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a
      planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed
      every 2 cycles of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal overall response rate</measure>
    <time_frame>During chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, Overall survival, Toxicity assessment, &amp; Pharmacokinetic characteristics and association with genetic polymorphism</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Colorecal Neoplasms</condition>
  <condition>Secondary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, irinotecan, oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed unresectable or metastatic colorectal cancer, not amenable to
             surgery or radiation treatment for curative intent

          -  At least one unidimensional measurable lesion

          -  ECOG performance status 0-2.

          -  No prior chemotherapy in metastatic settings, but adjuvant or neo-adjuvant treatment
             for non-metastatic (M0) disease is allowed if completed at least 6 months prior to
             initiation of study treatment

          -  Adequate major organ functions

          -  Give written informed consent

        Exclusion Criteria:

          -  Prior systemic chemotherapy for metastatic disease

          -  Prior treatment with oxaliplatin or irinotecan

          -  Prior radiotherapy is permitted if it was not administered to target lesions selected
             for this study and provided it has been completed at least 4 weeks before registration

          -  Prior surgical treatment of stage IV disease is permitted

          -  CNS metastases

          -  Prior history of peripheral neuropathy â‰¥ NCI CTC grade 1

          -  Uncontrolled or severe cardiovascular disease

          -  Serious concurrent infection or nonmalignant illness

          -  Other malignancy within the past 3 years except cured non-melanomatous skin cancer or
             carcinoma in situ of the cervix

          -  Organ allografts requiring immunosuppressive therapy

          -  Psychiatric disorder or uncontrolled seizure that would preclude compliance

          -  Pregnant, nursing women or patients with reproductive potential without contraception

          -  Patients receiving a concomitant treatment with drugs interacting with S-1 such as
             flucytosine, phenytoin, or warfarin et al.

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known
             dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Known hypersensitivity to platinum compounds or any of the components of the study
             medications

          -  Major surgery within 3 weeks prior to study treatment starts, or lack of complete
             recovery from the effects of major surgery

          -  Received any investigational drug or agent/procedure, i.e. participation in another
             trial within 4 weeks before beginning treatment with study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Hae Jung, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>not affiliated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung Hae Jung, M.D.Ph.D</last_name>
    <phone>+82-31-920-1611</phone>
    <email>khjung@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hwa Jung Kim</last_name>
    <phone>+82-31-920-1145</phone>
    <email>ncccoloonco@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Hae Jung, M.D.Ph.D</last_name>
      <phone>+82-31-920-1611</phone>
      <email>khjung@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hwa Jeong Kim</last_name>
      <phone>+82-31-920-1145</phone>
      <email>ncccoloonco@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Yong Sang Hong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Young Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hye Suk Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Yong Jeong, M.D.Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyo Seong Choi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seok-Byung Lim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee Jin Chang, M.D.Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Yong Jeong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>July 23, 2007</last_update_submitted>
  <last_update_submitted_qc>July 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <keyword>colorectal neoplasms</keyword>
  <keyword>secondary</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>irinotecan</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

